Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata - Jammu Kashmir Latest News | Tourism

  MUMBAI (Maharashtra) [India]/ Lexington [Kentucky], Jan 20: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO ) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of USD 8.00 per share of common stock in cash, or USD 576 million […]

Related Keywords

India ,United States ,Mumbai ,Maharashtra ,Washington ,America ,Sun Pharma ,Roger Tung ,Janet Metz ,Abhishek Sharma ,Abhay Gandhi ,Justine Koenigsberg ,Gaurav Chugh ,Concert Pharmaceuticals ,Twitter ,Sun Pharmaceutical Industries Limited Reuters ,Sun Pharmaceutical Industries Ltd ,Nasdaq ,Foliage Merger Sub Inc ,Moelis Company ,Chestnut Partners Inc ,Concert Investor Relations Department ,Health Partners ,Drug Administration ,Davis Polk Wardwell ,Exchange Commission ,Sun Pharma Investor Relations Department ,Concert Pharmaceuticals Inc ,Goodwin Procter ,Sun Pharmaceutical Industries Limited ,Adds Deuruxolitinib ,Potential Best In Class Oral ,Alopecia Areata ,Autoimmune Dermatological ,Global Infrastructure ,Provide Broad Access ,Global Dermatology Franchise ,Late Stage Product ,Significant Unmet ,Commence Tender Offer ,Acquire All Outstanding Shares ,Common Stock ,Upfront Cash Payment ,Equity Consideration ,Contingent Value Right ,Certain Time Based Net Sales ,North America ,New Drug Application ,Concert Board ,Davis Polk ,Chestnut Partners ,Sun Pharmaceutical Industries ,Foliage Merger Sub ,Tender Offer Statement ,Recommendation Statement ,Investor Relations Department ,Tender Offer ,Large Cross Sectional Survey Study ,Investigational Dermatology ,Cosmet Investig ,